Related Experiment Video

Updated: May 27, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications

Y-F Lau1, K-H Yiu, C-W Siu

  • 1Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.

Journal of Human Hypertension
|December 2, 2011
PubMed

Insights

Hypertension is a major risk factor for atrial fibrillation (AF). Understanding the link between high blood pressure and AF can improve cardiovascular event prevention and management strategies.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Atrial Fibrillation Studies

Background:

  • Hypertension is a primary risk factor for atrial fibrillation (AF), increasing cardiovascular event risk.
  • The precise pathophysiological mechanisms linking hypertension and AF remain incompletely understood.
  • Long-standing hypertension can lead to left atrial hemodynamic changes, elevated pressures, and enlargement.

Purpose of the Study:

  • To elucidate the pathophysiological link between hypertension and atrial fibrillation.
  • To explore the role of the renin-angiotensin-aldosterone system (RAAS) in hypertension-induced AF.
  • To review therapeutic strategies for AF in hypertensive patients.

Main Methods:

  • Review of existing literature on hypertension and atrial fibrillation.
  • Analysis of hemodynamic and electrophysiological changes in the left atrium due to hypertension.
  • Examination of the impact of RAAS activation on atrial tissue.
  • Evaluation of evidence for RAAS inhibitors in AF prevention.

Main Results:

  • Hypertension causes left atrial enlargement and fibrosis via RAAS activation, promoting AF.
  • RAAS blockade with ACE inhibitors or ARBs shows potential in AF prevention, though results vary.
  • Effective management includes blood pressure control, antithrombotic therapy, and rate control.

Conclusions:

  • Hypertension-induced RAAS activation contributes significantly to AF development through atrial remodeling.
  • Targeting RAAS may offer a therapeutic strategy for AF prevention in hypertensive individuals.
  • Comprehensive management of hypertensive patients with AF requires integrated approaches including BP and rate control.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...